1
|
Zhao L, Li X, Yang L, Sun L, Mu S, Zong H, Li Q, Wang F, Song S, Yang C, Zhao C, Chen H, Zhang R, Wang S, Dong Y, Zhang Q. Evaluation of remodeling and regeneration of electrospun PCL/fibrin vascular grafts in vivo. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2020; 118:111441. [PMID: 33255034 PMCID: PMC7445127 DOI: 10.1016/j.msec.2020.111441] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Revised: 08/16/2020] [Accepted: 08/21/2020] [Indexed: 12/14/2022]
Abstract
The success of artificial vascular graft in the host to obtain functional tissue regeneration and remodeling is a great challenge in the field of small diameter tissue engineering blood vessels. In our previous work, poly(ε-caprolactone) (PCL)/fibrin vascular grafts were fabricated by electrospinning. It was proved that the PCL/fibrin vascular graft was a suitable small diameter tissue engineering vascular scaffold with good biomechanical properties and cell compatibility. Here we mainly examined the performance of PCL/fibrin vascular graft in vivo. The graft showed randomly arranged nanofiber structure, excellent mechanical strength, higher compliance and degradation properties. At 9 months after implantation in the rat abdominal aorta, the graft induced the regeneration of neoarteries, and promoted ECM deposition and rapid endothelialization. More importantly, the PCL/fibrin vascular graft showed more microvessels density and fewer calcification areas at 3 months, which was beneficial to improve cell infiltration and proliferation. Moreover, the ratio of M2/M1macrophage in PCL/fibrin graft had a higher expression level and the secretion amount of pro-inflammatory cytokines started to increase, and then decreased to similar to the native artery. Thus, the electrospun PCL/fibrin tubular vascular graft had great potential to become a new type of artificial blood vessel scaffold that can be implanted in vivo for long term.
Collapse
Affiliation(s)
- Liang Zhao
- College of Life Science and Technology, Xinxiang Medical University, Xinxiang, China; Key Laboratory of Cardiac Structure Research, Zhengzhou Seventh People's Hospital, Zhengzhou, China.
| | - Xiafei Li
- College of Medical Engineering, Xinxiang Medical University, Xinxiang, China
| | - Lei Yang
- College of Life Science and Technology, Xinxiang Medical University, Xinxiang, China; First Affiliated Hospital, Xinxiang Medical University, Xinxiang, China
| | - Lulu Sun
- College of Life Science and Technology, Xinxiang Medical University, Xinxiang, China
| | - Songfeng Mu
- College of Life Science and Technology, Xinxiang Medical University, Xinxiang, China; First Affiliated Hospital, Xinxiang Medical University, Xinxiang, China
| | - Haibin Zong
- College of Medical Engineering, Xinxiang Medical University, Xinxiang, China
| | - Qiong Li
- Nursing School, Xinxiang Medical University, Xinxiang, China
| | - Fengyao Wang
- The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, China
| | - Shuang Song
- College of Life Science and Technology, Xinxiang Medical University, Xinxiang, China
| | - Chengqiang Yang
- College of Life Science and Technology, Xinxiang Medical University, Xinxiang, China
| | - Changhong Zhao
- College of Life Science and Technology, Xinxiang Medical University, Xinxiang, China
| | - Hongli Chen
- College of Life Science and Technology, Xinxiang Medical University, Xinxiang, China
| | - Rui Zhang
- Service Center for Transformation of Scientific and Technological Achievements, Xinxiang Medical University, Xinxiang, China
| | - Shicheng Wang
- General Surgery Department, West District Hospital of Nanyang The First People's Hospital, Nanyang, China
| | - Yuzhen Dong
- First Affiliated Hospital, Xinxiang Medical University, Xinxiang, China.
| | - Qiqing Zhang
- College of Life Science and Technology, Xinxiang Medical University, Xinxiang, China.
| |
Collapse
|
2
|
Jafarihaghighi F, Ardjmand M, Mirzadeh A, Hassani MS, Parizi SS. Current challenges and future trends in manufacturing small diameter artificial vascular grafts in bioreactors. Cell Tissue Bank 2020; 21:377-403. [PMID: 32415569 DOI: 10.1007/s10561-020-09837-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2019] [Accepted: 05/09/2020] [Indexed: 01/17/2023]
Abstract
Cardiovascular diseases are a leading cause of death. Vascular surgery is mainly used to solve this problem. However, the generation of a functional and suitable substitute for small diameter (< 6 mm) displacement is challengeable. Moreover, synthetic prostheses, made of polyethylene terephthalate and extended polytetrafluoroethylene show have shown insufficient performance. Therefore, the challenges dominating the use of autografts have prevented their efficient use. Tissue engineering is highlighted in regenerative medicine perhaps in aiming to address the issue of end-stage organ failure. While organs and complex tissues require the vascular supply to support the graft survival and render the bioartificial organ role, vascular tissue engineering has shown to be a hopeful method for cell implantation by the production of tissues in vitro. Bioreactors are a salient point in vascular tissue engineering due to the capability for reproducible and controlled variations showing a new horizon in blood vessel substitution. This review strives to display the overview of current concepts in the development of small-diameter by using bioreactors. In this work, we show a critical look at different factors for developing small-diameter and give suggestions for future studies.
Collapse
Affiliation(s)
- Farid Jafarihaghighi
- Department of Chemical Engineering, South Tehran Branch, Islamic Azad University, Tehran, Iran
| | - Mehdi Ardjmand
- Department of Chemical Engineering, South Tehran Branch, Islamic Azad University, Tehran, Iran.
| | - Abolfazl Mirzadeh
- Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC, 3052, Australia
| | - Mohammad Salar Hassani
- Department of Chemical Engineering, South Tehran Branch, Islamic Azad University, Tehran, Iran
| | - Shahriar Salemi Parizi
- Department of Chemical Engineering, South Tehran Branch, Islamic Azad University, Tehran, Iran
- Young Researchers and Elite Club, South Tehran Branch, Islamic Azad University, Tehran, Iran
| |
Collapse
|
3
|
In Vivo Performance of Decellularized Vascular Grafts: A Review Article. Int J Mol Sci 2018; 19:ijms19072101. [PMID: 30029536 PMCID: PMC6073319 DOI: 10.3390/ijms19072101] [Citation(s) in RCA: 80] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Revised: 07/16/2018] [Accepted: 07/16/2018] [Indexed: 12/12/2022] Open
Abstract
Due to poor vessel quality in patients with cardiovascular diseases, there has been an increased demand for small-diameter tissue-engineered blood vessels that can be used as replacement grafts in bypass surgery. Decellularization techniques to minimize cellular inflammation have been applied in tissue engineering research for the development of small-diameter vascular grafts. The biocompatibility of allogenic or xenogenic decellularized matrices has been evaluated in vitro and in vivo. Both short-term and long-term preclinical studies are crucial for evaluation of the in vivo performance of decellularized vascular grafts. This review offers insight into the various preclinical studies that have been performed using decellularized vascular grafts. Different strategies, such as surface-modified, recellularized, or hybrid vascular grafts, used to improve neoendothelialization and vascular wall remodeling, are also highlighted. This review provides information on the current status and the future development of decellularized vascular grafts.
Collapse
|